Corona Remedies Q1 Results FY27: PAT at Rs 60 Cr for June 2026 Quarter
- August 3, 2026
- Posted by: Ankit Jaiswal
- Category: News
Corona Remedies Q1 FY27: PAT Rs 60 Cr, +29.55% YoY. Revenue Rs 422 Cr, +21.90% YoY. Stock at Rs 2,210 (up 5.30%).
The Corona Remedies Q1 results FY27 show consolidated revenue of Rs 422 Cr for the quarter ended 30 June 2026, +21.90% from Rs 346 Cr in Q1 FY26, as Corona Remedies reported its numbers on 31 July 2026.
Corona Remedies posted a net profit (PAT) of Rs 60 Cr for the quarter, against Rs 46 Cr a year earlier. Shares traded around Rs 2,210 on the NSE, up 5.30% on the day, as investors weighed the print against trends in the pharmaceuticals sector. Here is a full breakdown of the financial highlights, key business factors, dividend status, outlook and risks.
Click Here – Get Free Investment Predictions
Corona Remedies Q1 Results FY27 Financial Highlights
The table below summarises Corona Remedies’s consolidated numbers for the quarter against the year ago period.
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|
| Revenue | Rs 422 Cr | Rs 346 Cr | +21.90% |
| Gross Profit | Rs 79 Cr | Rs 60 Cr | +31.27% |
| Gross Profit Margin | 18.7% | 17.3% | +1.4 pts |
| Net Profit (PAT) | Rs 60 Cr | Rs 46 Cr | +29.55% |
| Net Profit Margin | 14.2% | 13.3% | +0.9 pts |
Corona Remedies Q1 FY27 Performance Analysis
Revenue growth was the standout number for the quarter. Sales rose +21.90% year on year to Rs 422 Cr, up from Rs 346 Cr in the year ago period, as demand held firm through the June quarter.
Margins expanded through the June quarter. Gross profit rose +31.27% year on year to Rs 79 Cr (18.7% margin), a faster clip than the revenue increase, which points to better cost absorption.
The bottom line followed through on the operating performance. Net profit increased +29.55% year on year to Rs 60 Cr, up from Rs 46 Cr in Q1 FY26, translating the quarter’s operating trends into a stronger PAT print.
Check the Univest Screener for Live Data
Corona Remedies Q1 FY27: Key Business Factors
1. Revenue Growth Trajectory
Corona Remedies reported revenue of Rs 422 Cr for the June 2026 quarter against Rs 346 Cr in the year ago period, a change of +21.90%. This pace of change is a primary swing factor behind the quarter’s numbers, and investors typically track whether it holds up in the following quarters.
2. Gross Margin and Cost Trends
Gross profit moved from Rs 60 Cr in Q1 FY26 to Rs 79 Cr in Q1 FY27, a change of +31.27%. In the pharmaceuticals sector, this line is sensitive to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets, and this quarter’s numbers reflect how Corona Remedies managed that balance.
3. Bottom Line and Earnings Quality
Net profit moved from Rs 46 Cr in Q1 FY26 to Rs 60 Cr this quarter, up +29.55%. On a reported basis this is the figure that flows through to earnings per share, and it is usually the first number investors check.
Dividend Details
Specific dividend information was not confirmed as part of this results snapshot. Investors should check the official exchange filing on the NSE or BSE website, or track the Univest Screener, for the latest dividend announcement, record date and payment date from Corona Remedies.
Corona Remedies Outlook for FY27
Management commentary and the underlying trends this quarter will guide how FY27 shapes up for Corona Remedies. Investors should track whether the growth in revenue and the improvement in profit continue into the September quarter, along with any updates on capacity, cost or demand that management shares in the coming weeks.
Corona Remedies Stock Performance After the Results
Corona Remedies shares traded around Rs 2,210 on the NSE, up 5.30% around the time the results were in focus. The 52 week trading range was not confirmed as part of this snapshot; investors can check the live 52 week high and low, along with technical levels, on the Univest Screener before making any trading decision.
Download the Univest iOS App or Univest Android App to track Corona Remedies live share price and upcoming quarterly results.
Key Risks
Investors reading through Corona Remedies’s numbers should also weigh the following risks.
1. Margin and Input Cost Risk
Being in the pharmaceuticals sector, Corona Remedies remains exposed to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets. A reversal in the trend seen this quarter could pressure margins in coming quarters.
2. Execution and Working Capital Risk
Execution risk around working capital, receivables and order timelines can cause quarter to quarter volatility in reported numbers, so this quarter’s trends should be read over a few quarters rather than in isolation.
3. Macro and Sector Risk
Broader macro factors including interest rates, currency movements and demand cycles in the pharmaceuticals sector could influence how sustainable this quarter’s trends prove to be over FY27.
Conclusion
The Corona Remedies Q1 results FY27 show revenue of Rs 422 Cr and Rs 60 Cr for the quarter, against Rs 346 Cr and Rs 46 Cr in Q1 FY26. Revenue growth and a stronger bottom line were the two moving parts this quarter. Investors tracking Corona Remedies should watch the next few quarters for confirmation of this trend and consult a SEBI-registered advisor before making investment decisions based on these numbers.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Corona Remedies Q1 Results FY27
When were the Corona Remedies Q1 results FY27 announced?
Ans. They reflect the quarter ended 30 June 2026, with the data reported as of 31 July 2026. Investors should confirm the exact board meeting date from the official NSE or BSE filing.
What is the PAT in Corona Remedies’s Q1 FY27 results?
Ans. The PAT stood at Rs 60 Cr, compared with Rs 46 Cr in Q1 FY26, a change of +29.55%.
What was the revenue in Corona Remedies’s Q1 FY27 results?
Ans. Revenue came in at Rs 422 Cr for the quarter, a change of +21.90%, compared with Rs 346 Cr in Q1 FY26.
Did Corona Remedies declare a dividend with the Q1 FY27 results?
Ans. Dividend details were not confirmed as part of this results snapshot. Check the latest exchange filing on NSE or BSE, or the Univest Screener, for confirmation.
What is the outlook for Corona Remedies after Q1 FY27?
Ans. Analysts will track whether the growth in revenue and improvement in profit continue into the September 2026 quarter, along with input cost and demand trends in the pharmaceuticals sector.
How did the stock react to Corona Remedies’s Q1 FY27 results?
Ans. Shares traded around Rs 2,210 on the NSE, up 5.30% as the numbers came into focus.
Is Corona Remedies a good buy after the Q1 FY27 results?
Ans. The quarter shows a net profit of Rs 60 Cr on revenue of Rs 422 Cr. This article is for educational purposes only and is not investment advice. Consult a SEBI-registered advisor before making any investment decision.
